促性腺激素类型与窦卵泡计数调整后的卵泡募集及获卵数:4525个拮抗剂周期的分析
该回顾性队列研究分析4525个拮抗剂IVF/ICSI周期,比较CFA、rFSH和HP-HMG三种促性腺激素的卵巢反应效率。经AFC调整后,CFA的FORT和FOI最高,HP-HMG最低,且CFA的卵泡计数相关OHSS风险最低。
要点
- CFA的FORT和FOI最高,优于HP-HMG,匹配或超过rFSH。
- 低AMH(<1.1 ng/ml)时FOI-MII:CFA 81.4%,rFSH 64.5%,HP-HMG 49.2%。
- OHSS风险(>18个≥11mm卵泡):CFA 6.5%,HP-HMG 19.8%,rFSH 39.2%。
核心结论
- 经AFC调整后,CFA在多数AMH分层中达到最高的FORT和FOI,持续优于HP-HMG并匹配或超过rFSH,同时保持最低的卵泡计数相关OHSS风险。
研究设计与样本
- 回顾性队列研究,分析4525个拮抗剂IVF和ICSI周期,使用CFA(n=728)、rFSH(n=1848)或HP-HMG(n=1949)。
- 采用广义估计方程控制患者聚类,协变量包括年龄、AMH、体重、刺激时长、促性腺激素剂量和择期冷冻。
主要发现
- CFA的卵巢反应指数最高:FORT 16-22(61.6%),FOI-COC 106.4%,FOI-MII 81.1%。
- rFSH的FORT为49.3%,FOI-COC 98.0%,FOI-MII 74.6%。
- HP-HMG的FORT为39.6%,FOI-COC 71.5%,FOI-MII 46.5%。
- 低AMH(<1.1 ng/ml)时FOI-MII:CFA 81.4%,rFSH 64.5%,HP-HMG 49.2%。
- 正常/高AMH(1.1-3 ng/ml)时FOI-MII:CFA 86.3%,rFSH 64.5%,HP-HMG 53.1%。
关键数值与推荐
- FORT和FOI分别计算为卵泡或获卵数与窦卵泡计数(AFC)的比值。
- OHSS风险定义为>18个≥11 mm的卵泡,CFA为6.5%,HP-HMG为19.8%,rFSH为39.2%。
临床怎么用
- 在拮抗剂方案中,CFA可能提高卵泡输出率和获卵效率,尤其在低AMH患者中。
- 选择促性腺激素时需权衡卵巢反应效率与OHSS风险,CFA的卵泡计数相关OHSS风险最低。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 未报告活产率、临床妊娠率等妊娠结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Do FSH types (recombinant FSH [rFSH] versus highly purified human menopausal gonadotrophin (HP-HMG) versus corifollitropin alfa (CFA) differ in the efficiency of ovarian response, as assessed by follicular output rate (FORT) and follicle-to oocyte index (FOI)? DESIGN: Retrospective cohort study analysing 4525 antagonist IVF and intracytoplasmic sperm injection cycles using CFA (n = 728), rFSH (n = 1848) or HP-HMG (n = 1949). The FORT and FOI indices were calculated as ratios of follicle or oocyte yield to antral follicle count (AFC). Generalized estimating equations were used to account for clustering by patient with covariates for age, anti-Müllerian hormone (AMH), weight, stimulation duration, gonadotrophin dose and elective freeze. RESULTS: The CFA yielded the highest ovarian response indices (FORT 16-22 [61.6%], FOI-COC [106.4%], FOI-MII [81.1%]), compared with rFSH (49.3%, 98.0%, 74.6%) and HP-HMG (39.6%, 71.5%, 46.5%). Stratified analyses confirmed this ranking across AMH strata. In low AMH (<1.1 ng/ml), FOI-MII was 81.4% with CFA, 64.5% with rFSH and 49.2% with HP-HMG. In normal/high AMH (1.1-3 ng/ml) FOI-MII was 86.3%, 64.5% and 53.1%. Generalized additive model analyses demonstrated a modest non-linear AMH effect only for CFA, peaking at about 1.5-2.0 ng/ml before declining, whereas rFSH rose gradually and HP-HMG remained quite flat. Age-stratified analyses showed a uniform decline across FSH types. The risk of OHSS (>18 follicles ≥11 mm) was lowest with CFA (6.5%), compared with 19.8% for HP-HMG and 39.2% for rFSH. CONCLUSION: After adjusting for AFC, CFA achieved the highest FORT and FOI across most AMH strata, consistently outperforming HP-HMG and matching or exceeding rFSH, while maintaining the lowest follicle-count-based OHSS risk.
引用
- Dhaenens L, Rottiers AS, Vandierendonck F, et al. Gonadotrophin type and antral follicle count-adjusted follicular recruitment and oocyte yield in 4525 antagonist cycles. Reprod Biomed Online. 2026. PMID: 41965201. doi:10.1016/j.rbmo.2026.105478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。